There is great concern about the impact of COVID-19 among the nearly 40 million people living with HIV (PLWH) worldwide. In this review, we surveyed current literature and found no evidence of higher prevalence of COVID-19 among PLWH but equivocal data on increased mortality and worse clinical outcomes. Having HIV does not confer protection against severe manifestations of COVID-19. Several studies looking at antiretroviral drugs against HIV to treat SARS-CoV-2 have shown no mortality benefit. Thus, there is no indication to change antiretroviral therapy (ART) regimens among virologically suppressed PLWH to prevent COVID-19. HIV care delivery has been adversely impacted in several countries during this pandemic but has created an opportunity for accelerating effective strategies like multi-month ART. Decentralizing HIV care in low-resource settings and incorporating telemedicine in high-resource settings will be critical in mitigating shocks to healthcare systems in the future.
【저자키워드】 COVID-19, HIV, Pathogenesis, Epidemiology, 【초록키워드】 SARS-CoV-2, pandemic, Mortality, clinical outcomes, Shock, Antiretroviral therapy, ART, Care, Critical, PLWH, Evidence, manifestation, Healthcare system, regimen, increased mortality, treat, antiretroviral drug, country, Prevent, benefit, shown, suppressed, with HIV, impacted, effective strategy, prevalence of COVID-19, 【제목키워드】 Impact,